NOKOMIS, Fla., & SUNNYVALE, Calif.--(BUSINESS WIRE)--Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), and Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury, have finalized the framework of their proposed joint venture (JV) and will execute material definitive agreements within 30 days.
